Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound Docetaxel in Advanced Solid Tumors
NCT05114915Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jan 2022
- Primary completion
- Oct 2023
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of albumin-bound docetaxel in solid tumor (advanced stage) (3 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Incidence and frequency of adverse events and serious adverse events at 2 years, Maximum Tolerated Dose and Recommended Phase 2 Dose and 4 more. Status: unknown.
02
Drugs
albumin-bound docetaxel
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05114915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05114915.